Maspardin antibody
Principal name
Maspardin antibody
Alternative names for Maspardin antibody
SPG21, ACP33, BM-019, GL010, Spastic paraplegia 21 autosomal recessive Mast syndrome protein, Acid cluster protein 33
Ncbi ID
9606, NP_057714, NM_001127890, NP_001121361, NP_001121361.1, NP_613050.1, NM_138584, NM_001006987, NM_001127889
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB)
Background of Maspardin antibody
- Kit Component:
- - KN316597G1, Spg21 gRNA vector 1 in pCas-Guide vector
- KN316597G2, Spg21 gRNA vector 2 in pCas-Guide vector
- KN316597D, donor vector containing left and right homologous arms and Luciferase-Puro functional cassette
- GE100003, scramble sequence in pCas-Guide vector - CRISPR Manual:
- CRISPR/CAS9 Genome Editing Manual
General readings
Simpson MA., et al. (2003). Am J Hum Genet. 73(5):1147-56.
Zeitlmann L., et al. (2001). J Biol Chem. 276(12):9123-32.
SPG21 polyclonal antibody (A01), Lot # 060516JCS1 Western Blot analysis of SPG21 expression in HL-60 ( Cat # L014V1 ).
Recombinant human SPG21, aa 1-308, His-tagged: 15% SDS-PAGE (3 µg)
WB Suggested Anti-SPG21 Antibody; Titration: 1.0 ug/ml; Positive Control: 721_B Whole Cell SPG21 is supported by BioGPS gene expression data to be expressed in 721_B
WB Suggested Anti-SPG21 Antibody; Titration: 1.0 ug/ml; Positive Control: HepG2 Whole Cell
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP300071 | Maspardin (transcript variant 1) |
||||
| Recombinant protein of human spastic paraplegia 21 (autosomal recessive, Mast syndrome) (SPG21), transcript variant 1 | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€748.00
|
|
| OriGene Technologies, Inc. | |||||
| TP325431 | Maspardin (transcript variant 2) |
||||
| Recombinant protein of human spastic paraplegia 21 (autosomal recessive, Mast syndrome) (SPG21), transcript variant 2 | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€748.00
|
|
| OriGene Technologies, Inc. | |||||
Lysates
| Catalog No. | ||
|---|---|---|
| LY426877 | SPG21 overexpression lysate |
|
 |
0.1 mg /
€315.00
|
|
| OriGene Technologies, Inc. |
Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR204356L2V | Lenti ORF particles, Spg21 (GFP-tagged) - Mouse spastic paraplegia 21 homolog (human) (Spg21), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€930.00
|
|
| OriGene Technologies, Inc. | ||
| MR204356L1V | Lenti ORF particles, Spg21 (Myc-DDK-tagged) - Mouse spastic paraplegia 21 homolog (human) (Spg21), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€830.00
|
|
| OriGene Technologies, Inc. | ||
Rat Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| RR201873L2V | Lenti ORF particles, Spg21 (GFP-tagged ORF) - Rat spastic paraplegia 21 homolog (human) (Spg21), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€930.00
|
|
| OriGene Technologies, Inc. | ||
| RR201873L1V | Lenti ORF particles, Spg21 (Myc-DDK-tagged ORF) - Rat spastic paraplegia 21 homolog (human) (Spg21), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€830.00
|
|
| OriGene Technologies, Inc. | ||
